TürkçeProstate cancer examination, diagnosis, and imaging methods consist of the PSA blood test, physical urological examination, multiparametric prostate MRI that provides a detailed assessment of the anatomical structure of the organ, and biopsy procedures that provide a definitive cellular diagnosis. During the staging process, which determines the extent of the disease throughout the body, innovative molecular nuclear medicine technologies such as PSMA PET/CT come into play. The integrated use of these medical tools provides a highly accurate map of the tumor’s characteristics and location. Thanks to these comprehensive findings, the clinical picture of the disease is clarified, allowing the most appropriate personalized oncological treatment plan to be developed on a reliable basis.
What is prostate cancer and what are the risk factors?
The prostate is a small gland located just below the urinary bladder and surrounding the urethra, forming part of the male reproductive system. Prostate cancer is a structural disease that develops when the cells within this gland multiply uncontrollably in an abnormal manner. As one of the most common solid tumors among men, this disease is one of the most extensively studied health conditions worldwide. Its clinical course is highly variable; in some cases, it remains slow-growing and silent for years without requiring treatment, while in others it may progress much more aggressively.
The incidence of the disease increases steadily with advancing age. Autopsy examinations of individuals who died from unrelated causes have shown that even men in their thirties may have microscopic cancerous cell foci. However, the disease is most commonly diagnosed or detected through screening in individuals between the ages of 55 and 74. In addition to aging, genetic factors also play a significant role. Individuals with a family history of prostate cancer have a considerably higher risk of developing the disease compared to the general population. Certain inherited genetic factors, such as BRCA gene mutations, may also predispose the disease to develop a more aggressive cellular behavior.
The main risk factors associated with the disease are as follows:
- Advanced age
- Family history
- Genetic mutations
- Environmental factors
How is the course of the disease and prostate cancer risk groups evaluated?
After a diagnosis of prostate cancer has been established, patients are classified into specific risk groups in order to predict how the disease is likely to progress and to determine the most appropriate treatment strategy. This classification serves as a clinical roadmap. Patients in the low-risk group generally have very small tumors, non-aggressive cellular characteristics, and acceptable blood test values. Rather than initiating aggressive treatment immediately, these patients are often managed with a close monitoring strategy known as active surveillance.
In intermediate-risk patients, the tumor may have spread to a somewhat larger area within the gland, or biopsy findings may indicate increased cellular activity. In the high-risk group, the tumor tends to approach or extend beyond the prostate capsule, accompanied by increased cellular aggressiveness. In these high-risk cases, prompt planning of comprehensive multidisciplinary treatments such as surgery or radiotherapy is generally recommended.
The primary parameters used to determine risk groups include:
- Tumor size
- Biopsy score
- Antigen level
Why is early diagnosis important and when should prostate screening begin?
Early diagnosis is one of the most critical factors determining the success of prostate cancer treatment. When the tumor is detected while it is still very small and confined entirely within the prostate gland, the likelihood of successful curative treatment is extremely high. Opportunistic screening, even in individuals without symptoms, is valuable in preventing a disease that may otherwise progress silently.
General health guidelines recommend that men at average risk begin routine prostate screening at the age of 50. However, if an individual’s father or brother has a history of prostate cancer, indicating an increased genetic risk, beginning screening at the age of 40 is generally considered more appropriate. The purpose of screening is not only to detect disease but also to support long-term health and longevity. Therefore, routine screening may not always be recommended for very elderly individuals with serious coexisting illnesses or an expected life expectancy of less than ten years, considering the potential burden associated with treatment.
What role does the physical examination play in diagnosing prostate cancer?
Despite the numerous blood tests and imaging technologies available today, the physical examination continues to play an indispensable role in the diagnosis of prostate cancer. During the brief procedure known as the digital rectal examination, the physician can directly evaluate the structure of the posterior surface of the prostate gland. Due to its anatomical location immediately in front of the rectum, the prostate can be easily palpated through this approach.
A healthy prostate typically feels elastic, smooth, and soft during examination, whereas tissues suspicious for cancer may present with firmness, asymmetry, or focal pea-like nodules on the surface. Since a large proportion of prostate cancers originate precisely in this palpable outer region, the importance of the physical examination is further emphasized. Even if blood test results appear completely normal, further diagnostic evaluation is generally recommended when a suspicious area of firmness is detected during examination.
What is the PSA blood test and what does it mean when prostate cancer is suspected?
Prostate-specific antigen, commonly known as PSA, is a protein produced by cells of the prostate gland whose primary function is to regulate the consistency of semen. Only a very small amount of this protein normally enters the bloodstream. By measuring its concentration through a blood test, physicians can gain insight into the overall health of the prostate.
The most important characteristic of this protein is that it is specific to the prostate gland, but it is not specific to prostate cancer. Therefore, an elevated PSA level indicates that something may be affecting the prostate, but it does not prove that the cause is cancer. Values above a certain reference range (generally between 4.0 and 10.0 ng/mL) are considered a gray zone, while much higher levels may indicate a greater risk. When an abnormal result is detected, repeating the test several weeks later is generally recommended before drawing conclusions, in order to exclude temporary fluctuations.
Does an elevated PSA level always mean prostate cancer?
A very common misconception among the public is that an elevated PSA level directly indicates prostate cancer. In reality, many benign conditions that irritate, inflame, or enlarge the prostate gland may also cause increased release of prostate-specific antigen into the bloodstream.
Benign prostatic enlargement associated with aging is one of the most common causes of elevated PSA levels. Likewise, bacterial or non-bacterial prostatitis, urinary retention, strenuous physical activity, or even recent urinary catheterization may temporarily cause PSA levels to rise significantly.
Conditions that may cause elevated PSA levels include:
- Benign enlargement
- Prostatitis
- Urinary tract infection
- Urinary obstruction
- Catheterization
- Surgical procedures
Which additional tests are requested when the PSA level remains in the gray zone?
When the total PSA level falls within the uncertain range known as the gray zone, several additional calculations are used to avoid unnecessary invasive procedures and to better clarify the situation. These assessments help distinguish the underlying cause of the elevated PSA.
One commonly used approach is calculating the ratio of free PSA to total PSA. Malignant cells generally tend to produce PSA that is more frequently bound to other proteins, making a lower free PSA ratio more suspicious for cancer. Another useful parameter is PSA density, which evaluates PSA production relative to prostate volume, helping differentiate elevations caused simply by an enlarged prostate. Monitoring the rate of PSA increase over time is also considered a valuable clinical indicator.
Additional tests commonly used in the gray zone include:
- Free PSA ratio
- PSA density
- PSA velocity
What advantages does prostate MRI provide in suspicious cases?
When tumor suspicion arises based on physical examination findings or blood test results, multiparametric magnetic resonance imaging (MRI) is now commonly performed. This advanced imaging technique is highly effective for mapping the prostate’s anatomical structure at the cellular level. It not only demonstrates the size of the gland but can also reveal tissue density and changes in vascular architecture.
During the examination, diffusion-weighted sequences that analyze cellular density and dynamic contrast-enhanced sequences that evaluate the movement of intravenously administered contrast material through tissues are used together. Because malignant cells are much more densely packed than normal cells, they restrict the movement of water molecules, allowing MRI to identify these restricted areas as distinct bright or dark focal lesions. Likewise, newly formed abnormal blood vessels appear as rapidly enhancing areas following contrast administration. These features help physicians avoid unnecessary procedures or accurately target suspicious regions if biopsy becomes necessary.
What does the PI-RADS score in prostate MRI reports indicate?
After MRI images have been evaluated, radiologists report detected lesions using a standardized international reporting system known as PI-RADS. This system assigns each lesion a score from 1 to 5, providing a universal language for communication between radiologists and treating physicians.
Lower scores indicate a very low likelihood of clinically significant prostate cancer, whereas higher scores suggest that tissue sampling from the lesion is strongly recommended. These reports may also accurately predict how close the tumor is to the prostate capsule or whether it has extended into surrounding fatty tissue. Consequently, they provide valuable guidance when planning surgery by helping determine the appropriate surgical margins.
How is a prostate biopsy performed and what is its role in diagnosis?
When abnormal blood test results, suspicious physical examination findings, or a high-risk lesion identified on MRI are present, the only definitive method of obtaining a microscopic cellular diagnosis is a prostate biopsy. Imaging techniques can identify suspicious regions, but only pathological examination of biopsy tissue can confirm the diagnosis.
The procedure is generally performed under ultrasound guidance. Regional anesthesia is used to numb the area and maximize patient comfort. Small tissue samples are then obtained from different parts of the prostate using specially designed fine needles. These slender tissue cores are carefully examined by expert pathologists to determine whether abnormal cellular changes are present. The procedure is typically brief and well tolerated by patients.
Which modern methods are currently used instead of the standard prostate biopsy?
For many years, the conventional biopsy approach involved inserting the needle directly through the rectal wall to reach the prostate. However, because of the natural bacterial flora within the rectum, this technique carried a certain risk of infection and required extensive antibiotic use.
Today, with advances in medical technology, the transperineal approach is increasingly preferred. In this modern technique, the biopsy needle passes directly through the skin of the perineum rather than the rectal wall to reach the prostate. This avoids contact with intestinal bacteria, substantially reducing the likelihood of postoperative fever or infection. It also greatly decreases the need for extensive antibiotic use.
The main advantages of the transperineal technique include:
- Low risk of infection
- Reduced need for antibiotics
- Preservation of the rectal mucosa
- Safer tissue sampling
How is MRI-TRUS fusion biopsy, also known as smart biopsy, performed?
If suspicious targets have already been identified on MRI, MRI-TRUS fusion technology is used to obtain highly accurate tissue samples directly from these lesions. This technology functions much like an intelligent navigation system.
During the procedure, the patient’s three-dimensional MRI map is digitally fused with live ultrasound images. Specialized software enables the physician to visualize suspicious lesions on the ultrasound screen as colored targets that would otherwise not be visible. This fusion allows the biopsy needle to be directed precisely into the center of the suspicious lesion, significantly reducing the likelihood of missing clinically significant disease. To ensure comprehensive diagnosis and patient safety, tissue samples are also obtained from surrounding areas of the prostate in addition to the targeted lesions.
What does locally advanced prostate cancer mean and how is staging planned?
After prostate cancer has been diagnosed, one of the most important next steps is staging the disease to determine its extent. If the tumor has extended beyond the prostate capsule or into the seminal vesicles located behind the prostate, but has not yet spread to distant organs, it is medically classified as locally advanced prostate cancer.
Simple physical examination and ultrasound alone may not provide sufficient information for accurate staging. Advanced molecular tests capable of analyzing the genetic characteristics of tumor cells, together with highly detailed cross-sectional imaging studies, may be utilized to better predict the biological behavior of the disease. Careful mapping determines whether the tumor remains regionally confined or has the potential for distant spread, allowing treatment planning to be tailored accordingly.
How is surgical treatment planned after prostate cancer is diagnosed?
When a localized tumor is identified, surgery generally becomes the central component of a multidisciplinary treatment strategy. The primary goal is to remove all cancerous tissue while maintaining adequate surgical margins. Depending on the patient’s risk profile, surgery may include removal of not only the prostate gland but also nearby lymph nodes and, when necessary, adjacent structures.
Today, these extensive procedures are performed predominantly using robotic surgical technology. With high-definition magnified visualization and highly dexterous robotic instruments, the surgical team aims to remove cancerous tissue while preserving the nerves responsible for urinary continence and sexual function whenever possible. Following surgery, the removed tissues are sent for pathological examination to determine whether any residual cancer cells remain and to evaluate the surgical margins. These findings play a crucial role in determining whether additional treatment is necessary.
Is radiotherapy or hormone therapy necessary after prostate cancer surgery?
Whether a patient should simply enter follow-up or receive additional treatment after surgery is determined primarily by the postoperative pathology report. If the report indicates that the tumor has clearly extended beyond the prostate capsule, that cancer cells may remain at the surgical margins, or that lymph node involvement is present, additional treatment may be recommended to reduce the risk of recurrence.
In these situations, localized radiation therapy and hormone-suppressing treatments designed to inhibit cancer cell growth are commonly used. Long-term clinical studies have demonstrated that in high-risk patients, combining radiotherapy with hormone therapy significantly suppresses cancer activity and contributes positively to long-term survival outcomes. The duration of these treatments is determined by a multidisciplinary medical team according to each patient’s individual risk profile.
How are patients monitored after prostate cancer treatment?
Patients who have completed primary treatment such as surgery or radiotherapy continue to undergo regular follow-up for many years. Even long after treatment has ended, maintaining these follow-up visits is extremely important for preserving long-term health.
Under the standard approach, patients are seen more frequently during the initial years after treatment. During these visits, physicians review the patient’s symptoms and carefully monitor blood test results. PSA levels are expected to remain at extremely low or undetectable levels. Routine CT scans or bone scans are generally unnecessary when patients have no symptoms and PSA levels remain normal. However, if new physical symptoms develop, further diagnostic evaluation is promptly initiated.
Common components of routine follow-up include:
- Review of symptoms
- Physical examination
- Blood testing
Which advanced imaging methods are used when prostate cancer recurs?
If PSA levels begin rising again during follow-up after successful initial treatment, biochemical recurrence becomes a concern. At this stage, the key question is whether the elevated PSA originates from a tiny cluster of cells remaining near the original prostate site or from disease that has spread elsewhere. Standard imaging studies are often unable to detect such microscopic disease when PSA levels remain very low.
In these situations, PSMA PET imaging, one of the most advanced tools in nuclear medicine, becomes particularly valuable. Following intravenous administration of mildly radioactive compounds that specifically bind to structures on the surface of prostate cancer cells, cancerous tissue becomes visible on imaging. This allows even millimeter-sized lesions that cannot be detected using conventional imaging techniques to be identified with high accuracy. Prior to imaging, medications that increase urine production may also be administered to reduce physiological urinary tract activity and improve image quality.
PSMA PET imaging is commonly used in the following situations:
- Suspicion of recurrence after treatment
- Evaluation for metastasis
- Assessment of lymph node involvement
- Planning salvage treatment
What are theranostic treatments used in advanced prostate cancer?
In very advanced cases where the disease becomes resistant to conventional hormone therapy or other treatments, theranostic approaches represent one of the most promising innovations in modern oncology. The term “theranostics” combines the concepts of diagnosis and therapy. This approach utilizes intelligent molecules capable of specifically recognizing and attaching to tumor cells.
These smart molecules, labeled with nuclear medicine agents such as Lutetium or Actinium, travel through the bloodstream directly into cancerous tissue and deliver highly targeted radiation at the cellular level. This allows powerful destruction of malignant cells while minimizing damage to surrounding healthy tissues. These advanced treatments require highly specific approval according to national healthcare regulations. Patients must meet defined genetic and cellular criteria and possess an adequate performance status to tolerate treatment. In appropriately selected individuals, these innovative therapies may play an important role in improving quality of life and supporting long-term disease management.
Frequently Asked Questions
